Literature DB >> 3299439

The timing, specificity and clinical prediction of tricyclic drug effects in depression.

M M Katz, S H Koslow, J W Maas, A Frazer, C L Bowden, R Casper, J Croughan, J Kocsis, E Redmond.   

Abstract

This research was aimed at studying the rate of action of tricyclic drugs in depressive disorders, specifying the behavioural effects associated with recovery, and predicting clinical response. The research design involved comparison of a recovered group with a group treated for the equivalent four weeks, who showed minimal to no response. The findings indicated significant differences in baseline characteristics between responders and non-responders. Further, the drugs were found to act early in the responders, within the first week of treatment. Specific changes at one week which distinguished responder and non-responder groups occurred in the disturbed affects, and in cognitive functioning. Improvements also occurred in somatic symptoms, but these latter changes were general and not associated with later recovery. At 2 1/2 weeks, all facets of the depressed condition showed positive change in the responders. Implications of the results for assessing rate of tricyclic drug actions, their effects on the interaction of affect and neurochemistry, and the practical application of the results for the clinical situation, are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3299439     DOI: 10.1017/s0033291700024831

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  16 in total

1.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

2.  Who receives antidepressants and what impact do they have? An acute-care study.

Authors:  Patricia M Averill; Adel A Wassef
Journal:  Psychiatr Q       Date:  2006

3.  Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone.

Authors:  G E Duncan; D J Knapp; S W Carson; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  Prospects for the development of new treatments with a rapid onset of action in affective disorders.

Authors:  J C Soares; S Gershon
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 5.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 7.  Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

Authors:  Matthew J Taylor; Nick Freemantle; John R Geddes; Zubin Bhagwagar
Journal:  Arch Gen Psychiatry       Date:  2006-11

8.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.

Authors:  Roberto Gomeni; Emilio Merlo-Pich
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

Review 9.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

10.  Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.

Authors:  J Brielmaier; J M Senerth; J L Silverman; P G Matteson; J H Millonig; E DiCicco-Bloom; J N Crawley
Journal:  Genes Brain Behav       Date:  2014-03       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.